Sanfer Receives $500M from CDPQ to Fund Strategic Growth across Latin America

Sanfer, one of Mexico's leading independent pharmaceutical companies, has obtained a USD $500 million minority investment from Caisse de dépôt et placement du Québec (CDPQ), a long-term institutional investor. The investment, one of the largest minority private equity transactions in Mexico, will enable Sanfer to execute on its continued expansion plans across Mexico and the broader Latin American region.

Over the past two decades, Sanfer has had a longstanding commitment to offering innovative and high-quality pharmaceutical products to its customers. Over this period, the Company has closed over 100 brand acquisitions, acquired 8 pharmaceutical companies and launched over 100 new products across Mexico and Latin America. Sanfer intends to use this new capital to accelerate its growth, both organic and through further acquisitions, across the region.

Ricardo Amtmann A., Chairman and CEO of Sanfer, said: "The addition of CDPQ as a strategic partner marks an important moment for Sanfer as we look to further strengthen our position across Mexico and Latin America. CDPQ, together with our existing partner General Atlantic, will contribute invaluable expertise as we pursue strategic growth opportunities that will allow Sanfer to meaningfully scale the business and deepen our reach with customers. We are honored to have CDPQ's trust in our Company and to see their commitment to the Latin American region."

Stephane Etroy, Executive Vice-President and Head of Private Equity at CDPQ, said: "Our partnership with Sanfer is an opportunity for us to grow our exposure to targeted countries in Latin America, while investing in a key sector of these economies. We are proud to be partnering with a company of Sanfer's caliber, alongside General Atlantic. We are confident in the pharmaceutical industry's long-term outlook and look forward to working with Sanfer's leadership team to capitalize on growth opportunities."

Martín Escobari, General Atlantic Managing Director and Head of Latin America, commented: "Our five-year strategic partnership with Sanfer has produced strong results as the Company, under the dynamic leadership of Ricardo, has focused on growth and product development. Sanfer is now uniquely positioned to capture an even greater share of the pharmaceutical industry in the region. CDPQ shares GA's long-term vision for the Company and we welcome them as partners in this next exciting chapter for Sanfer."

GA will retain a significant minority stake in Sanfer, and the transaction is expected to close later this year. This investment is subject to customary regulatory approvals. Additional terms were not disclosed.

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content, 

please email: Julia.Zhang@ubmsinoexpo.com to delete.